The departure of GlaxoSmithKline (GSK) from the Nigerian pharmaceutical market that led to the subsequent surge in the prices of GSK medications up to 1000% have raised serious concerns among the Nigerian population. The reasons behind the price increase are multifaceted, involving both GSK’s strategic decision to leave and broader economic factors affecting the country.
GSK’s shift to a third-party direct distribution model in Nigeria was motivated by operational challenges, including difficulties in maintaining a consistent supply of drugs and challenges related to foreign exchange scarcity. The scarcity of foreign exchange made it challenging for GSK to manage and settle foreign currency-denominated trade payables with its suppliers, contributing to the decision to discontinue direct commercialization in Nigeria.
External factors such as regional insecurity, the removal of fuel subsidies by the government, and the overall high cost of doing business in Nigeria also played a role in GSK’s decision. These factors collectively forced GSK to realign its strategy in the Nigerian pharmaceutical market.
The impact of GSK’s exit is evident in the scarcity of GSK drugs across the country, leading to significant challenges for community pharmacies, particularly in Lagos, to procure these medicines. Traders of pharmaceutical products have reported decreased availability of GSK drugs, resulting in higher prices for these medications.
The rising inflation rate in Nigeria, reaching 27.33% as of October 2023, further exacerbates the situation. Inflation has been a driving force behind the increasing costs of various goods and services, including pharmaceutical products. The compounded effects of GSK’s departure and the high inflation rate pose substantial challenges to the affordability and availability of medicines in Nigeria.
To illustrate the impact, a comparison of current prices (as of November 2023) with those before GSK’s exit reveals significant price hikes, with some medications experiencing increases as high as 1000%. This surge in prices has led to widespread frustration among Nigerians, expressed through social media platforms.
The challenges posed by GSK’s departure and the economic factors affecting the pharmaceutical market in Nigeria highlight the need for strategic interventions and policy measures to ensure the continued availability and affordability of essential medications for the population.
